Mesenchymal transformed breast cancer cells with GnRH agonist Triptorelin treatment, CTGF blocking antibody or transiently suppressed CTGF expression reduced invasiveness, increased cell-ECM adhesion and reduced ECM degradation (Fig. 8A). Here, CCN2 is linked to breast carcinoma.